Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer

Taxel, Pamela; Faircloth, Erika; Idrees, Sana; Poznak, Catherine Van

doi:10.1210/js.2018-00052

Cited by 24 publications

(19 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been noticed that survivors of breast cancer often suffer from OS (26). One explanation for this is that many survivors of breast cancer experience a loss of ovarian function and a drop in estrogen levels due to chemotherapy or surgery, which promotes the development of OS (27). Another explanation is that breast cancer cells can secrete γ-secretase, cyclooxygenase-2 and interleukin-8, promoting the process of osteoclastogenesis (28,29).…”

Section: Discussionmentioning

confidence: 99%

Pathway and network analysis of genes related to osteoporosis

Guo

Han

Guo³

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

As a common degenerative disease, osteoporosis (OS) is characterized by reduced bone mass and microarchitectural deterioration of bone tissue. Both genetic and environmental factors are involved in OS development. To date, ~300 genes have been confirmed to be involved in the pathogenesis of OS, a large majority of which have been independently investigated. As OS is a polygenetic disease, a comprehensive analysis focusing on the biological functions and interactions of OS-related genes would provide valuable information. In this study, OS related research deposited in PubMed was retrieved and genes related to OS were catalogued. Pathways with an enriched biological function for these genes were extracted, and the crosstalk between the enriched pathways was analyzed. A comprehensive network was constructed, and a minimal network was extracted using the Steiner minimal network algorithm. In this study, a total of 294 genes in were retrieved from PubMed. Biological processes found to be enriched included those related to bone metabolism and the immune system. In total, 58 pathways were enriched. Furthermore, the comprehensive network consisting of 3,943 nodes and 7,976 edges was constructed, among which 631 nodes and 2,581 edges contributed to the OS-specific molecular network. In this network, in excess of 300 potential genes associated with OS and two modules were identified. Thus, this study provides a mechanistic insight into OS and suggests more than 300 potential OS-related genes for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Pathway and network analysis of genes related to osteoporosis

Guo

Han

Guo³

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Oncotherapy could lead to a long-term decrease in the physical functional capacity in gastric and colorectal cancer patients [43,44]. Chemotherapy, hormonal therapy, and radiation therapy could induce bone loss and muscle weakness in survivors of breast or prostate cancer, which were prevalent in working-age individuals [45,46]. Oncotherapy could also cause cardiovascular side-effects [47,48] and peripheral neuropathy [49].…”

Section: Restricted Physical Functional Capacitymentioning

confidence: 99%

Working cancer survivors’ physical and mental characteristics compared to cancer-free workers in Japan: a nationwide general population-based study

Ota

Yatsuya

et al. 2021

J Cancer Surviv

View full text Add to dashboard Cite

Purpose This study compared working cancer survivors’ self-rated health status (SRHS), physical functional capacity, depressive symptoms, and happiness to those of cancer-free workers. Methods A nationwide general population-based cross-sectional study on a sample of Japanese was conducted. Prevalence of deteriorated SRHS, restricted physical functional capacity, depressive symptoms, and perceived happiness were compared between working cancer survivors and cancer-free workers with multivariable logistic regression analysis adjusted for age and sociodemographic and health-related backgrounds. Results Of the 28,311 male and 26,068 female workers, 977 (3.5%) and 1267 (4.9%) were cancer survivors, respectively. Working cancer survivors reported deteriorated SRHS more frequently than cancer-free workers: 21.3% vs. 13.8%, multivariable-adjusted odds ratio (95% confidence interval), 1.64 (1.39–1.95) for men, 23.8% vs. 17.5%, 1.34 (1.16–1.54) for women. Restricted physical functional capacity was reported more frequently in working cancer survivors than cancer-free workers: 6.8% vs. 2.6%, 1.76 (1.34–2.32) for men, 4.9% vs. 2.0%, 2.06 (1.56–2.71) for women. No significant difference was found for depressive symptoms: 21.6% vs. 22.9% in men, 30.0% vs. 28.5% in women. Working cancer survivors felt happiness more frequently than cancer-free survivors in men (77.3% vs. 71.7%, 1.21 (1.01–1.45)) but not in women (76.1% vs. 74.9%). Conclusions Working cancer survivors had worse SRHS and more restricted physical functional capacity than cancer-free workers. In men, working cancer survivors felt happiness more frequently than cancer-free workers. Implications for Cancer Survivors Continuous support to improve cancer survivors’ SRHS and physical functional capacity would be necessary even while they are working.

show abstract

“…CTIBL is particularly important in young women, considering their long life expectancy and is more rapid and severe than bone loss associated with menopause [27]. CTIBL is mainly caused by chemotherapy with resultant ovarian failure or endocrine treatment with gonadotropin-releasing hormone [GnRH] analogs, aromatase inhibitors and tamoxifen [28]. In contrast to postmenopausal women, tamoxifen is associated with a decreased Bone Mass Density (BMD) in premenopausal women when the menstrual cycles resume after treatment discontinuation [28,29].…”

Section: Bisphosphonatesmentioning

confidence: 99%

“…In addition to that, GnRH analogs and chemotherapyinduced ovarian dysfunction have been linked to substantial bone mass loss annually [28]. Therefore, it has been suggested that some women receive antiresorptive therapy with bisphosphonates [28]. Furthermore, there is a growing body of evidence, which highlights the antineoplastic attributes of bisphosphonates in early breast cancer, as zoledronic acid has been correlated with improved disease-free survival in patients taking anastrozole or tamoxifen and decreased probability of bone metastases [28,30,31].…”

Section: Bisphosphonatesmentioning

confidence: 99%

“…Therefore, it has been suggested that some women receive antiresorptive therapy with bisphosphonates [28]. Furthermore, there is a growing body of evidence, which highlights the antineoplastic attributes of bisphosphonates in early breast cancer, as zoledronic acid has been correlated with improved disease-free survival in patients taking anastrozole or tamoxifen and decreased probability of bone metastases [28,30,31]. Despite the benefits of bisphosphonates, their pharmacological attributes and lack of pregnancy-relevant clinical evidence renders them as a controversial choice for this age group [32].…”

Section: Bisphosphonatesmentioning

confidence: 99%

See 1 more Smart Citation

Supportive medication in cancer during pregnancy

Zagouri

Dedes

Papatheodoridi

et al. 2020

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

While pregnancy-related malignancies are quite rare, their incidence is increasing and thus affecting more and more women nowadays. Their management, however, with both chemotherapy and supportive agents remains quite challenging and it seems crucial to define the optimal treatment for this special population. Concerning supportive medication, it is clinically significant to determine whether commonly used agents, including Granulocyte Colony-Stimulating Factors, Erythropoiesis-stimulating agents, Bisphosphonates, Anticoagulation agents, Antiemetics and Glucocorticoids are indeed effective in ameliorating chemotherapy side effects. Meanwhile, it is of great importance that the administration of any of these agents is safe for both mother and fetus. This review aims to provide a précis of the current literature regarding both safety and efficacy of all categories of supportive medication during pregnancy.

show abstract

Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer

Cited by 24 publications

References 67 publications

Pathway and network analysis of genes related to osteoporosis

Pathway and network analysis of genes related to osteoporosis

Working cancer survivors’ physical and mental characteristics compared to cancer-free workers in Japan: a nationwide general population-based study

Supportive medication in cancer during pregnancy

Contact Info

Product

Resources

About